Abstract:Abstract Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic backgrounds of individuals whose cancers are prone to migration. The most prevalent signaling cascade governed by multi-kinase inhibitors is the mitogen-activated protein kinase (MAPK) pathway, encompassing the RAS–RAF–MAPK kinase (MEK)–extracellular signal-related kinase (ERK) pathway. RAF kinase is a primary mediator of the MAPK pathway, responsible for the sequential activation of downstream targets, such as MEK and the transcription factor ERK, which control numerous cellular and physiological processes, including organism development, cell cycle control, cell proliferation and differentiation, cell survival, and death. Defects in this signaling cascade are associated with diseases such as cancer. RAF inhibitors (RAFi) combined with MEK blockers represent an FDA-approved therapeutic strategy for numerous RAF -mutant cancers, including melanoma, non-small cell lung carcinoma, and thyroid cancer. However, the development of therapy resistance by cancer cells remains an important barrier. Autophagy, an intracellular lysosome-dependent catabolic recycling process, plays a critical role in the development of RAFi resistance in cancer. Thus, targeting RAF and autophagy could be novel treatment strategies for RAF -mutant cancers. In this review, we delve deeper into the mechanistic insights surrounding RAF kinase signaling in tumorigenesis and RAFi-resistance. Furthermore, we explore and discuss the ongoing development of next-generation RAF inhibitors with enhanced therapeutic profiles. Additionally, this review sheds light on the functional interplay between RAF-targeted therapies and autophagy in cancer.

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

The MAPK pathway across different malignancies: A new perspective

Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors

The MAPK Signalling Pathways and Colorectal Cancer

Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Antineoplastic Agents Targeting on MAPK Signal Transduction System

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer

p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents.

Role of p38 MAP kinase in cancer stem cells and metastasis

MAPK Signaling in Inflammation-Associated Cancer Development